OBJECTIVES OF PREFERRED PRACTICE PATTERN ® GUIDELINES
As a service to its members and the public, the American Academy of Ophthalmology has developed a series of Preferred Practice Pattern® guidelines that identify characteristics and components of quality eye care. Appendix 1 describes the core criteria of quality eye care.
The Preferred Practice Pattern® guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical trials are available, the data are particularly persuasive and provide clear guidance. In other instances, the panels have to rely on their collective judgment and evaluation of available evidence.
These documents provide guidance for the pattern of practice, not for the care of a particular individual. While they should generally meet the needs of most patients, they cannot possibly best meet the needs of all patients. Adherence to these PPPs will not ensure a successful outcome in every situation. These practice patterns should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. It may be necessary to approach different patients' needs in different ways. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all of the circumstances presented by that patient. The American Academy of Ophthalmology is available to assist members in resolving ethical dilemmas that arise in the course of ophthalmic practice.
Preferred Practice Pattern® guidelines are not medical standards to be adhered to in all individual situations. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any recommendations or other information contained herein.
References to certain drugs, instruments, and other products are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved U.S. Food and Drug Administration (FDA) labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.
Innovation in medicine is essential to ensure the future health of the American public, and the Academy encourages the development of new diagnostic and therapeutic methods that will improve eye care. It is essential to recognize that true medical excellence is achieved only when the patients' needs are the foremost consideration. 
All Preferred Practice

METHODS AND KEY TO RATINGS
Preferred Practice Pattern guidelines should be clinically relevant and specific enough to provide useful information to practitioners. Where evidence exists to support a recommendation for care, the recommendation should be given an explicit rating that shows the strength of evidence. To accomplish these aims, methods from the Scottish Intercollegiate Guideline Network 1 (SIGN) and the Grading of Recommendations Assessment, Development and Evaluation 2 (GRADE) group are used. GRADE is a systematic approach to grading the strength of the total body of evidence that is available to support recommendations on a specific clinical management issue. Organizations that have adopted GRADE include SIGN, the World Health Organization, the Agency for Healthcare Research and Policy, and the American College of Physicians. 3 All studies used to form a recommendation for care are graded for strength of evidence individually, and that grade is listed with the study citation. To rate individual studies, a scale based on SIGN 1 is used. The definitions and levels of evidence to rate individual studies are as follows:
I++
High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias I+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias IMeta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias II++ High-quality systematic reviews of case control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal II+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal IICase-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal III Non-analytic studies (e.g., case reports, case series)
Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE 2 as follows:
Good quality Further research is very unlikely to change our confidence in the estimate of effect Moderate quality
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate Insufficient quality
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate Any estimate of effect is very uncertain Key recommendations for care are defined by GRADE 2 as follows:
Strong recommendation
Used when the desirable effects of an intervention clearly outweigh the undesirable effects or clearly do not Discretionary recommendation Used when the trade-offs are less certain-either because of low quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced
The Highlighted Recommendations for Care section lists points determined by the PPP Committee to be of particular importance to vision and quality of life outcomes. All recommendations for care in this PPP were rated using the system described above. Ratings are embedded throughout the PPP main text in italics. Literature searches to update the PPP were undertaken in February 2015 in the PubMed database. Complete details of the literature searches are available in Appendix 2.
HIGHLIGHTED RECOMMENDATIONS FOR CARE
The recommended frequency for adult comprehensive medical eye examinations for asymptomatic patients, and for patients who do not have risk factors for eye disease, is as follows: under 40 years-every 5-10 years; 40 to 54 years-every 2-4 years; 55 to 64 years-every 1-3 years; and 65 years or older-every 1-2 years. (moderate quality, strong recommendation)
The first recommended adult comprehensive medical eye examination, and subsequent frequency of examination for patients who have diabetes mellitus, varies depending on the type of diabetes and whether a woman is pregnant. The recommendations are as follows: (1) type 1 diabetes mellitus-first examination 5 years after onset and yearly afterwards; (2) type 2 diabetes mellitus-first examination at the time of diagnosis and yearly afterwards; and (3) for women with type 1 or type 2 diabetes-first examination prior to conception and then early in the first trimester of pregnancy. Interval recommendations thereafter will be based on findings at first examination. (moderate quality, strong recommendation) (Note: Women who develop gestational diabetes do not require an eye examination during pregnancy, and they do not appear to be at increased risk for developing diabetic retinopathy during pregnancy.) 
BACKGROUND
Comprehensive adult medical eye evaluation is the focus of this document. Patients may seek this evaluation for a variety of reasons. A comprehensive medical eye evaluation is recommended for patients who have not been examined for an extended period of time by an ophthalmologist or who are being seen for the first time. Recommended intervals between comprehensive examinations vary with age and risk factors. A thorough ophthalmic evaluation can detect common abnormalities of the visual system and related structures as well as less common yet extremely serious ones, such as ocular tumors. Such an evaluation can also uncover evidence of systemic disease that have associated ophthalmic manifestations. All patients, particularly those with risk factors for ocular disease, should be re-examined periodically to prevent or minimize vision loss by detecting and treating the disease at an early stage. Patients in whom ophthalmic disease(s) are identified require periodic comprehensive examinations for optimal monitoring and treatment of the condition(s). With appropriate and timely intervention, potentially blinding diseases such as glaucoma, cataract, agerelated macular degeneration (AMD) and diabetic retinopathy often have a more favorable outcome. Studies have indicated that up to 40% of legal blindness found among nursing home residents, 4 as well as in both urban 5 and rural 6 communities, could have been prevented or ameliorated if those individuals had received timely ophthalmic screening and care. In a population-based study, 63% of the participants who had eye disease were not aware of it.
7
RATIONALE FOR COMPREHENSIVE MEDICAL EYE EVALUATIONS
The rationale for performing periodic comprehensive medical eye examinations in adults without known ocular conditions or risk factors is to detect ocular diseases, visual dysfunction, or ophthalmic signs of systemic disease in the adult population. Early recognition, counseling, or treatment may preserve visual function or, in the case of systemic diseases, could prevent serious illness or even premature death. Irreversible vision loss has been associated with adverse effects on quality of life and mental health, 8, 9 and self-reported visual loss has been found to be significantly associated with depression. 10 Comprehensive medical eye evaluations are also performed periodically to evaluate new symptoms and monitor patients with previously identified eye conditions or risk factors.
The public health impact of eye disease is substantial, because vision affects daily functioning. [11] [12] [13] [14] [15] Improvement in visual function that occurs as a result of treatment of ocular disorders is accompanied by improvement in life satisfaction and mental health and by participation in home and community activities. [16] [17] [18] [19] Vision plays a critical role in mobility and in fall prevention. [20] [21] [22] [23] Untreated visual impairment has been associated with cognitive decline and Alzheimer's disease. 24 In women 65 and
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Comprehensive Adult Medical Eye Evaluation PPP: Ocular Diseases older, poorer visual acuity and reduced contrast sensitivity have been associated with a higher risk of mortality. 25 A higher risk of motor vehicle collisions was found among drivers with glaucoma who had severe visual field defects. 26 Cataract surgery in older drivers has been shown to reduce the subsequent motor vehicle collision rate. 27 Visual impairment, AMD, and cataract have been associated with an increased risk of mortality.
28,29
OCULAR DISEASES
In 2000, about 937,000 adults 40 and older in the United States were legally blind (best-corrected visual acuity of 20/200 or less in each eye), and an additional 2.4 million were visually impaired (best-corrected visual acuity of <20/40 in the better-seeing eye). 30 The highest frequencies of visual impairment and legal blindness were found in individuals 80 years and older and generally correlated with age. 30, 31 Rates of visual impairment and legal blindness were disproportionately higher among individuals of African descent compared with individuals of European descent. 5, 30, 32 Rates of visual impairment (defined as visual acuity <20/40 in the better-seeing eye) were higher among individuals of Hispanic/Latino descent compared with individuals of European or African descent. 30, 33 Many patients will be unaware that they have a vision-threatening ocular condition because of the lack of early symptoms (see Table 1 ). These conditions include common and often treatable diseases such as glaucoma, diabetic retinopathy, and some forms of macular degeneration.
Open-Angle Glaucoma
Primary open-angle glaucoma is a significant public health problem. It is estimated that 45 million people in the world have open-angle glaucoma (OAG). 34 Glaucoma (both open-angle and angle-closure) is the second leading cause of blindness worldwide, with approximately 8.4 million people blind from glaucoma. 34 Overall in 2004, the prevalence of POAG for adults aged 40 and older in the United States was estimated to be about 2%. 35 Open-angle glaucoma affects an estimated 2.2 million people in the United States, and that number is likely to increase to 3.3 million in 2020 as the population ages. 36, 37 However, large differences exist in the prevalence of glaucoma among different ethnoracial groups. Overall, there appears to be a threefold higher prevalence of OAG in African Americans relative to non-Hispanic whites in the United States. 35, 38 It is also the leading cause of blindness in African Americans. 38 Further, the prevalence of OAG is even higher in Afro-Caribbeans relative to African Americans. Recent evidence on Hispanics/Latinos suggests that they have high prevalence rates of OAG that are comparable to the prevalence rates for African Americans. 39 An analysis of claims data from a large U.S.-based managed care plan suggests that the prevalence of OAG among Asian Americans is comparable to the prevalence among Latinos and is higher than that of nonHispanic white Americans. 40 
Primary Angle Closure
There are considerable differences in the prevalence of angle closure among racial and ethnic groups. The highest rates are reported in Inuit, [41] [42] [43] Chinese, [44] [45] [46] [47] [48] and other Asian [49] [50] [51] [52] [53] [54] [55] [56] [57] populations; lower rates are reported in populations of African and African-derived origin 38, 58, 59 and European and European-derived origin. [60] [61] [62] [63] [64] [65] [66] Primary angle-closure glaucoma may account for the majority of glaucoma in Asian populations.
49,67,68
Diabetes Mellitus
The number of adults with diagnosed diabetes mellitus in the United States has nearly quadrupled from 5.5 million to 21.3 million from 1980 to 2012. It is estimated that about 8.1 million of these adults are not aware that they have diabetes. About 1.7 million new cases of diabetes in adults are diagnosed each year. If this trend continues, as many as 1 out of every 3 adults could have diabetes by 2050. The Centers for Disease Control and Prevention estimates that 86 million U.S. adults-more than 1 in 3-had prediabetes in 2012, based on impaired fasting blood glucose levels. 69 Obesity is a recognized risk factor for type 2 diabetes mellitus, but the risks are heterogenous such that not all obese patients will develop diabetes. 70 The prevalence rate of diabetic retinopathy for all adults 40 and older in the United States is 3.4% (4.1 million persons); the prevalence rate of vision-threatening retinopathy is 0.7% (899,000 persons). 71 Assuming a similar prevalence of diabetes mellitus, the projected numbers in 2020 would be 6 million persons with diabetic retinopathy and 1.34 million persons with vision-threatening diabetic retinopathy. Although effective treatment for reducing the risk of blinding diabetic retinopathy and diabetic macular edema is available, [72] [73] [74] [75] [76] [77] [78] [79] the number of patients with diabetes referred by their primary care physicians or who present for ophthalmic care falls far below that which would be predicted based on the guidelines of the American Diabetic Association and the American Academy of Ophthalmology. [80] [81] [82] [83] [84] Regular examination and follow-up of all patients with diabetes reinforces the importance of recommended dietary and medication compliance and can lead to earlier detection and treatment of retinopathy. Regular examinations, coupled with appropriate local and systemic medical therapy (including pharmacotherapy) and laser treatment for those who require it, have been shown to be extremely cost-effective in the diabetic population, particularly when compared with disability payments for those who would otherwise become blind. [85] [86] [87] Local pharmacotherapies, including intravitreal injections, are becoming more frequently used in the management of these conditions. 128 The prevalence, incidence, and progression of AMD and most associated features (e.g., large drusen) increase significantly with age. 119, 120, 128 For example, the prevalence of AMD in white females 60 to 64 is 0.3%, increasing to 16.4% in white females 80 and older. 128 Age-related macular degeneration is usually asymptomatic in its early stages, although a fundus examination is helpful in identifying patients with an increased risk of developing choroidal neovascularization or advanced AMD. 124 It is important to identify those patients at higher risk because the AREDS2 supplement formulation (i.e., vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin) has been shown to have preventive efficacy. 129 An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They should be considered to be at high risk for advanced AMD and are the population for whom the AREDS2 formulation should be considered. If all the patients at risk were given supplements, then more than 300,000 could delay disease progression and associated vision loss. 129 Cigarette smoking has been consistently identified in numerous studies as a risk factor for progression of AMD, and the risk increases relative to the number of pack-years smoked. [130] [131] [132] [133] [134] [135] [136] [137] Smoking-cessation counseling may influence patients to stop smoking, reducing the risk of AMD progression. Patients with neovascular AMD report a substantial decline in their quality of life and have an increased need for assistance with activities of daily living that progresses as visual acuity worsens. 138 Early treatment of AMD is associated with a more favorable prognosis. 139 Anti-VEGF treatment given within 2 years after diagnosis of neovascular AMD in non-Hispanic white patients has been shown to reduce legal blindness and visual impairment. 140 Because early symptoms may be subtle, a comprehensive eye examination may represent a patient's best opportunity to be diagnosed and treated at an earlier and potentially more favorable stage.
Cataract
Cataract remains a significant cause of visual disability in the United States, accounting for approximately 50% of low-vision cases in adults over 40. 30 Cataract is the leading cause of treatable blindness among Americans of African descent who are 40 years of age and older, and it is the leading cause of low vision among individuals of African, Hispanic/Latino, and European descent. 30 Because smoking increases the risk of cataract progression, 141, 142 informing smokers about this and other associated ocular and systemic diseases may influence them to stop smoking.
Other Ocular Disorders
Other examples of high-risk conditions or diseases that necessitate a medical eye examination include a past history of ocular trauma or the presence of abnormalities of the anterior segment, such as corneal ectasia, corneal dystrophies, or peripheral anterior synechiae. Conditions that increase the risk of open-angle glaucoma (e.g., exfoliation syndrome and pigment dispersion syndrome) and angle-closure glaucoma (narrow anterior chamber angle) should also be evaluated. High myopia and abnormalities of the posterior segment, such as retinal tears or retinal degenerations (i.e., lattice degeneration or subclinical asymptomatic retinal detachments), increase the risk of retinal detachment.
SYSTEMIC DISEASES AND CONDITIONS
Important ophthalmic manifestations associated with systemic infectious, neoplastic, autoimmune, vascular, and nutrition-related diseases may be discovered during the ocular examination. Therefore, findings that lead to the diagnosis of a number of systemic diseases may be revealed during a comprehensive ophthalmic evaluation. 
SOCIOECONOMIC CONSIDERATIONS
In 2006, the societal cost of major visual disorders (AMD, cataract, diabetic retinopathy, POAG, refractive errors) among U.S. residents 40 and older was estimated to be $35.4 billion. This total comprised $16.2 billion in direct medical costs, $11.1 billion in other direct costs, and $8 billion in productivity losses. 143 Not included in this total are costs associated with comorbid conditions, such as depression or injury.
In another study, U.S. residents 40 and older with blindness or visual impairment had estimated excess medical expenditures of $5.1 billion annually. 144 This estimate includes the cost of home care and informal care for blind and visually impaired adults. The study also estimated that the total number of quality-adjusted life years (QALY) lost for individuals with blindness or visual impairment was 209,000. Valuing each QALY lost at $50,000 would add $10.4 billion to the estimate of the annual economic impact of visual impairment and blindness.
In 2012, the costs of vision loss and eye disorders among the population younger than 40 years were estimated at $27.5 billion (95% confidence interval, $21.5-$37.2 billion), including $5.9 billion for children and $21.6 billion for adults 18 to 39 years of age in the United States. This total comprised of $14.5 billion in direct costs, including $7.3 billion for diagnosed eye disorders, $4.9 billion in refraction correction, and $0.5 billion for undiagnosed vision loss. The indirect costs were $13 billion, due mainly to productivity losses. In addition, this cumulative vision loss cost society 215,000 QALYs. 145 There were significant differences in the use of eye care services by adults with eye diseases in the United States with respect to socioeconomic position, as measured by poverty-income ratio and educational attainment. 146 In Australia, researchers estimated that the economic impact and cost in 2004 was A$9.85 billion health conditions. 147 Vision loss was also the seventh leading cause of disability in Australia, with 
OCULAR EXAMINATION
The comprehensive eye examination consists of an evaluation of the physiological function and the anatomical status of the eye, visual system, and its related structures. This usually includes the following elements:
Visual acuity with current correction (the power of the present correction recorded) at distance and, when appropriate, at near, with a refraction when indicated Visual fields by confrontation External examination (e.g., eyelid position and character, lashes, lacrimal apparatus and tear function; globe position; and pertinent facial features) Pupillary function (e.g., size and response to light, relative afferent pupillary defect) Ocular alignment and motility (e.g., cover/uncover test, alternate cover test, version and duction assessment) Slit-lamp biomicroscopic examination: eyelid margins and lashes; tear film; conjunctiva; sclera; cornea; anterior chamber; and assessment of central and peripheral anterior chamber depth, iris, lens, and anterior vitreous Intraocular pressure measurement, preferably with a contact applanation method (typically a Goldmann tonometer). Contact tonometry may be deferred in the setting of suspected ocular infection or corneal trauma. Fundus examination: mid and posterior vitreous, retina (including posterior pole and periphery), vasculature, and optic nerve Assessment of relevant aspects of patient's mental and physical status
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Examination of anterior segment structures routinely involves gross and biomicroscopic evaluation prior to and after dilation. Evaluation of structures situated posterior to the iris is best performed through a dilated pupil. Optimal examination of optic nerve, macula, and the peripheral retina requir the use of the indirect ophthalmoscope or slit-lamp fundus biomicroscopy with appropriate accessory diagnostic lenses.
Based on the patient's history and findings, additional tests or evaluations might be indicated to evaluate further a particular structure or function. 
DIAGNOSIS AND MANAGEMENT
The ophthalmologist evaluates and integrates the findings of the comprehensive ophthalmic examination with all aspects of the patient's health status and social situation in determining an appropriate course of action. (good quality, strong recommendation) Patients are considered in one o three general categories based on the results of the evaluation: patients with no risk factors, patients with risk factors, and patients with conditions that require intervention.
Category I: Patients with No Risk Factors
When the initial comprehensive evaluation is normal or involves only optical abnormalities that require corrective lenses, the ophthalmologist reviews the findings with the patient and renders advice regarding an appropriate interval for re-examination. Although this is considered a lowrisk category, periodic re-examination is indicated to detect new, potentially asymptomatic, or unrecognized ocular disease, such as glaucoma, diabetic retinopathy, and AMD, the incidence of which increases with age.
A 5-year observational study of a nationally representative cohort of Medicare beneficiaries showed that patients 65 and older who had more regular eye examinations experienced less decline in vision and functional status than those who had less frequent examinations. 149 For each additional year in which a patient received an eye examination, there was an increased likelihood of continuing to read newsprint and maintaining activities of daily living, and there was a decreased risk of developing new limitations in activities of daily living and instrumental activities of daily living. Instrumental activities of daily living are activities related to independent living and include preparing meals, managing money, shopping for groceries or personal items, performing light or heavy housework, and using a telephone.
There is no strong evidence in the literature to define the optimal frequency of eye examinations of patients under 65 with no eye symptoms or signs. There is some evidence that clinically significant fundus abnormalities in asymptomatic patients increase with age, 150 but other evidence suggests that the diagnostic yield of dilated fundus examination in asymptomatic patients is not high, particularly in younger age groups. 151 In the absence of symptoms or other indications following the initial comprehensive medical eye evaluation, periodic evaluations are recommended at the frequency indicated in Table 2 , which takes into account the relationship between increasing age and the risk of asymptomatic or undiagnosed disease. At the time of each comprehensive medical eye evaluation, the ophthalmologist will reassess the patient to determine the appropriate follow-up interval. (high quality, strong recommendation) Adults with no signs or risk factors for eye disease should receive a comprehensive medical eye evaluation at age 40 if they have not previously received one. 152 (moderate quality, strong recommendation)
Interim evaluations, such as screenings, refractions, or less extensive evaluations, are indicated to address episodic minor problems and complaints, or for patient reassurance. (high quality, strong recommendation) Other situations may warrant a comprehensive medical eye evaluation. The extent of the interim evaluation to be performed is determined by the patient's condition, symptoms, and by the ophthalmologist's medical judgment. Interim eye evaluations, consisting of vision examinations (e.g., refractions, eyeglasses, contact lens evaluations), may be performed during these periods as well.
Category II: Patients with Risk Factors
A patient is considered to be at increased risk when the evaluation reveals signs that are suggestive of a potentially abnormal condition or when risk factors for developing ocular disease are identified but the patient does not yet require intervention. These situations may merit closer follow-up to monitor the patient's ocular health and to detect early signs of disease with additional testing.
The ophthalmologist determines an appropriate follow-up interval for each patient based on the presence of early symptoms and signs, risk factors, the onset of ocular disease, and the potential
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Comprehensive Adult Medical Eye Evaluation PPP: Diagnosis and Management rate of progression of a given disease. (high quality, strong recommendation) For example, individuals of African descent might require more frequent examinations because they are at higher risk for an earlier onset and more rapid progression of glaucoma. It is recommended that patients with the conditions and risk factors noted in Table 3 undergo a comprehensive medical eye evaluation at the listed intervals. Vision rehabilitation attempts to restore as much functional ability as possible, 160 and patients with reduced visual function may be referred for vision rehabilitation and social services. 161 (high quality, strong recommendation) More information on vision rehabilitation, including materials for patients, is available at www.aao.org/smart-sight-low-vision.
PROVIDER AND SETTING
Of all health care providers, the ophthalmologist, as a physician with full medical training, best combines a thorough understanding of ocular pathology and disease processes; familiarity with systemic disorders that have ocular manifestations; and clinical skills and experience in ocular diagnosis, treatment, and medical decision making. This makes the ophthalmologist the most qualified professional to perform and oversee a comprehensive medical eye evaluation. (high quality, strong recommendation) Frequently, and appropriately, specific testing and data collection are conducted by trained personnel working under the ophthalmologist's supervision.
APPENDIX 1. QUALITY OF OPHTHALMIC CARE CORE CRITERIA
Providing quality care is the physician's foremost ethical obligation, and is the basis of public trust in physicians.
AMA Board of Trustees, 1986
Quality ophthalmic care is provided in a manner and with the skill that is consistent with the best interests of the patient. The discussion that follows characterizes the core elements of such care.
The ophthalmologist is first and foremost a physician. As such, the ophthalmologist demonstrates compassion and concern for the individual, and utilizes the science and art of medicine to help alleviate patient fear and suffering. The ophthalmologist strives to develop and maintain clinical skills at the highest feasible level, consistent with the needs of patients, through training and continuing education. The ophthalmologist evaluates those skills and medical knowledge in relation to the needs of the patient and responds accordingly. The ophthalmologist also ensures that needy patients receive necessary care directly or through referral to appropriate persons and facilities that will provide such care, and he or she supports activities that promote health and prevent disease and disability.
The ophthalmologist recognizes that disease places patients in a disadvantaged, dependent state. The ophthalmologist respects the dignity and integrity of his or her patients, and does not exploit their vulnerability.
Quality ophthalmic care has the following optimal attributes, among others.
The essence of quality care is a meaningful partnership relationship between patient and physician. The ophthalmologist strives to communicate effectively with his or her patients, listening carefully to their needs and concerns. In turn, the ophthalmologist educates his or her patients about the nature and prognosis of their condition and about proper and appropriate therapeutic modalities. This is to ensure their meaningful participation (appropriate to their unique physical, intellectual, and emotional state) in decisions affecting their management and care, to improve their motivation and compliance with the agreed plan of treatment, and to help alleviate their fears and concerns. The ophthalmologist uses his or her best judgment in choosing and timing appropriate diagnostic and therapeutic modalities as well as the frequency of evaluation and follow-up, with due regard to the urgency and nature of the patient's condition and unique needs and desires. The ophthalmologist carries out only those procedures for which he or she is adequately trained, experienced, and competent, or, when necessary, is assisted by someone who is, depending on the urgency of the problem and availability and accessibility of alternative providers. Patients are assured access to, and continuity of, needed and appropriate ophthalmic care, which can be described as follows. The ophthalmologist treats patients with due regard to timeliness, appropriateness, and his or her own ability to provide such care. The operating ophthalmologist makes adequate provision for appropriate pre-and postoperative patient care. When the ophthalmologist is unavailable for his or her patient, he or she provides appropriate alternate ophthalmic care, with adequate mechanisms for informing patients of the existence of such care and procedures for obtaining it.
The ophthalmologist refers patients to other ophthalmologists and eye care providers based on the timeliness and appropriateness of such referral, the patient's needs, the competence and qualifications of the person to whom the referral is made, and access and availability.
The ophthalmologist seeks appropriate consultation with due regard to the nature of the ocular or other medical or surgical problem. Consultants are suggested for their skill, competence, and accessibility. They receive as complete and accurate an accounting of the problem as necessary to provide efficient and effective advice or intervention, and in turn they respond in an adequate and timely manner. The ophthalmologist maintains complete and accurate medical records. On appropriate request, the ophthalmologist provides a full and accurate rendering of the patient's records in his or her possession. The ophthalmologist reviews the results of consultations and laboratory tests in a timely and effective manner and takes appropriate actions. The ophthalmologist and those who assist in providing care identify themselves and their profession. For patients whose conditions fail to respond to treatment and for whom further treatment is unavailable, the ophthalmologist provides proper professional support, counseling, rehabilitative and social services, and referral as appropriate and accessible. Prior to therapeutic or invasive diagnostic procedures, the ophthalmologist becomes appropriately conversant with the patient's condition by collecting pertinent historical information and performing relevant preoperative examinations. Additionally, he or she enables the patient to reach a fully informed decision by providing an accurate and truthful explanation of the diagnosis; the nature, purpose, risks, benefits, and probability of success of the proposed treatment and of alternative treatment; and the risks and benefits of no treatment. The ophthalmologist adopts new technology (e.g., drugs, devices, surgical techniques) in judicious fashion, appropriate to the cost and potential benefit relative to existing alternatives and to its demonstrated safety and efficacy. The ophthalmologist enhances the quality of care he or she provides by periodically reviewing and assessing his or her personal performance in relation to established standards, and by revising or altering his or her practices and techniques appropriately. The ophthalmologist improves ophthalmic care by communicating to colleagues, through appropriate professional channels, knowledge gained through clinical research and practice. This includes alerting colleagues of instances of unusual or unexpected rates of complications and problems related to new drugs, devices, or procedures. The ophthalmologist provides care in suitably staffed and equipped facilities adequate to deal with potential ocular and systemic complications requiring immediate attention. The ophthalmologist also provides ophthalmic care in a manner that is cost effective without unacceptably compromising accepted standards of quality. 
